Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity

Despite three decades of research to its name and increasing interest in immunotherapies that target it, LAG-3 remains an elusive co-inhibitory receptor in comparison to the well-established PD-1 and CTLA-4. As such, LAG-3 targeting therapies have yet to achieve the clinical success of therapies tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Burnell, Stephanie E A, Capitani, Lorenzo, MacLachlan, Bruce J, Mason, Georgina H, Gallimore, Awen M, Godkin, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
T Cell-Targeted Approaches to Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895726/
https://www.ncbi.nlm.nih.gov/pubmed/35265944
http://dx.doi.org/10.1093/immadv/ltab025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895726/
https://www.ncbi.nlm.nih.gov/pubmed/35265944
http://dx.doi.org/10.1093/immadv/ltab025

Ejemplares similares